Biogen news
The WiseView Research desk's stories that name Biogen, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The BIIB page →
- HeadlineBIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
- HeadlineBig Day for Econ Data, Hyperscaler Earnings
- HeadlineBiogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- HeadlineBiogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates
- Pre-market reportPre-Market: Fed Decision Looms as Vertiv Jumps, Boston Scientific Slides
Futures point modestly higher ahead of today's Fed rate decision, with Vertiv surging on earnings and Boston Scientific sliding.
- HeadlineBiogen Swings to Loss, Logs Higher Sales
- HeadlineBiogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
- Week aheadWeek Ahead: Fed Decision, GDP, PCE Inflation and Peak Earnings Week
The Fed's rate decision, Q3 GDP and core PCE inflation headline a week in which 178 S&P 500 companies report earnings.
- HeadlineBiogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?
- HeadlineBiogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm
- HeadlineBiogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- HeadlineA Look at Biogen Inc (BIIB) After 4.1% Gain -- GF Value $202.16 vs Price $243.10
- HeadlineBiogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
- HeadlineBiogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
- CongressRo Khanna bought $1,001 - $15,000 of BIIB
- CongressRo Khanna sold $1,001 - $15,000 of BIIB
- HeadlineBiogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
- HeadlineWill Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
- HeadlineBiogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
- CongressKevin Hern sold $1,001 - $15,000 of BIIB
- CongressGilbert Cisneros bought $1,001 - $15,000 of BIIB
- CongressGilbert Cisneros bought $1,001 - $15,000 of BIIB
- CongressRo Khanna bought $1,001 - $15,000 of BIIB
- CongressRob Bresnahan bought $1,001 - $15,000 of BIIB
- CongressRob Bresnahan sold $1,001 - $15,000 of BIIB
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.